The COVID-19 pandemic has taken the lives of nearly 500,000 people worldwide in the span of a few months. Recently, a novel isolate of the SARS-CoV-2 virus carrying a point mutation in the Spike protein (D614G) has emerged and rapidly surpassed others in prevalence, including the original SARS-CoV-2 isolate from Wuhan, China. This Spike variant is a defining feature of the most prevalent clade (A2a) of SARS-CoV-2 genomes worldwide and, recently, we and others have demonstrated this variant leads to virions with an ~8-fold increase in human cell transduction. This is the first experimental evidence of a SARS-CoV-2 population variant acting in a gain-of-function manner. Although there are hundreds of Spike variants now in circulation, we lack tools for high-throughput characterization of these variants and their virulence. Here, we propose to develop a massively-parallel, high- throughput approach to test all Spike variants using a pooled forward genetic screen, examine the impact of these mutations on proteolytic cleavage of Spike and on ACE2 receptor binding kinetics, and validate changes in viral transduction with live SARS-CoV-2 via an innovative trans-complementation assay. Our proposed studies aim to understand the interactions between Spike protein variants and host (human) cell infection and their underlying biochemical mechanisms. This research will enable us to predict whether particular Spike variants can drive more serious COVID-19 outbreaks.

Public Health Relevance

Although there are hundreds of Spike variants now in circulation, we lack tools for high-throughput characterization of these variants and their virulence. Our proposed studies aim to understand the interactions between Spike protein variants and host (human) cell infection and their underlying biochemical mechanisms. This research will enable us to predict whether particular Spike variants can drive more serious COVID-19 outbreaks.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
3DP2HG010099-01S2
Application #
10199425
Study Section
Program Officer
Pazin, Michael J
Project Start
2020-09-01
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
New York Genome Center
Department
Type
DUNS #
078473711
City
New York
State
NY
Country
United States
Zip Code
10013
Li, Li; Tian, E; Chen, Xianwei et al. (2018) GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease. Cell Stem Cell 23:239-251.e6
Sanjana, Neville E (2018) A genome-wide net to catch and understand cancer. Sci Transl Med 10:
Montalbano, Antonino; Canver, Matthew C; Sanjana, Neville E (2017) High-Throughput Approaches to Pinpoint Function within the Noncoding Genome. Mol Cell 68:44-59